JAMA Oncol 2020 Mar 26
Association of Presalvage Radiotherapy PSA Levels After Prostatectomy With Outcomes of Long-term Antiandrogen Therapy in Men With Prostate Cancer.
Related Questions
Are there other adverse features aside from seminal vesicle invasion, positive margins, or extraprostatic extension that you consider?
New answer by Radiation Oncologist at National Institutes of Health Clinical Center (May 23, 2021)
No, I don’t think there is any current available evidence to define a benefit for ADT in the post-operative setting for patients with an undetectable PSA. The two major ...
New comment by Radiation Oncologist at Lafayette Radiation Center ( September 7, 2021)
Agree with the above. Decipher is the future with reference to if and how much ADT to use in post RP and intact.
RADICALS-HD trial (ESMO 2022) demonstrated metastasis free survival benefit with 24 months compared to 6 months of ADT.
New comment by Radiation Oncologist at Kansas City VA Medical Center ( January 20, 2023)
I look at several prognostic factors, most importantly, GS score, PSA # of positive cores, and co-morbid conditions. I like to customize the length of ADT based on the above f...
Patient has multiple adverse features on pathology, however, PSA just became detectable one year after surgery. SPPORT included patients with PSA>0...
New answer by Radiation Oncologist at Memorial Sloan Kettering Cancer Center (April 17, 2024)
Agree with many of the comments above. I would consider adding ADT for detectable PSA <0.1 in patients with pT4, pN+, or GG5 disease who were under-represented or ineligibl...